Filing Details
- Accession Number:
- 0001055947-10-000013
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-04-07 13:00:00
- Reporting Period:
- 2010-04-05
- Filing Date:
- 2010-04-07
- Accepted Time:
- 2010-04-07 17:37:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1019695 | Arqule Inc | ARQL | Pharmaceutical Preparations (2834) | 043221586 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 918923 | P L Fund Value Biotechnology | 900 N. Michigan Ave., Suite 1100 Chicago IL 60611 | No | No | No | Yes | |
| 1055947 | P/Il L Partners Bvf | 900 N. Michigan Ave., Suite 1100 Chicago IL 60611 | No | No | Yes | No | |
| 1056807 | Bvf Inc/Il | 900 N. Michigan Ave., Suite 1100 Chicago IL 60611 | No | No | Yes | No | |
| 1102444 | Biotechnology Value Fund Ii Lp | 900 N. Michigan Ave., Suite 1100 Chicago IL 60611 | No | No | No | Yes | |
| 1132245 | Bvf Investments Llc | 900 N. Michigan Ave., Suite 1100 Chicago IL 60611 | No | No | No | Yes | |
| 1233840 | N Mark Lampert | 900 N. Michigan Ave., Suite 1100 Chicago IL 60611 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2010-04-05 | 147,000 | $6.13 | 4,664,073 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2010-04-05 | 102,000 | $6.13 | 4,562,073 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2010-04-05 | 354,000 | $6.13 | 4,208,073 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 4,208,073 | Indirect | General partner and manager of entities with direct ownership. |
| Common Stock | 4,208,073 | Indirect | General Partner of entity with indirect ownership. |
| Common Stock | 4,208,073 | Indirect | Sole shareholder and sole director of entity with indirect ownership. |
Footnotes
- Units may represent aggregation of daily trade activity. Details regarding individual execution amounts and prices are available upon request.
- Shares directly beneficially owned by Biotechnology Value Fund, L.P. ("BVF")
- Shares directly beneficially owned by Biotechnology Value Fund II, L.P. ("BVF II")
- The shares of Common Stock are directly beneficially owned by BVF Investments, LLC ("BVFLLC"), a Delaware limited liability company. Pursuant to the operating agreement of BVFLLC, BVF Partners, L.P., a Delaware limited partnership ("Partners") is authorized, among other things, to invest the contributed capital of Samana Capital, L.P., the majority member of BVFLLC, in the shares of Common Stock and other securities and to vote, exercise or convert and dispose of such securities and is entitled to receive fees based on assets under management and, subject to certain exceptions, allocations based on realized and unrealized gains on such assets.
- The shares of Common Stock are indirectly beneficially owned by Partners. Partners is the general partner of BVF and BVF II and is the manager of BVFLLC.
- The shares of Common Stock are indirectly beneficially owned by BVF Inc., a Delaware corporation ("BVF Inc."). BVF Inc. is the general partner of Partners.
- Mark N. Lampert is the sole shareholder, sole director, and an officer of BVF Inc.
Billionaire Hedge Funds
